Moreover, DCA to compare the clinical benefits of ApoA-I-based nomograms with those of traditional tumor staging showed superior clinical benefits of the ApoA-I-based nomograms for both PFS and OS, (Figure S10A, B). The gene discussed is APOA1; the disease is neoplasm.